These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 31975470)

  • 1. Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
    Lin C; Quan J; Bao Y; Hua W; Ke M; Zhang N; Jin Q; Xie Y; Wei Y; Ling T; Pan W; Wu L; Xie Y
    J Cardiovasc Electrophysiol; 2020 Mar; 31(3):658-663. PubMed ID: 31975470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of non-vitamin K antagonist oral anticoagulants on left atrial or atrial appendage thrombi in patients with nonvalvular atrial fibrillation].
    Cui J; Du X; Wu JH; Jia CQ; Li X; Ning M; Lyu J; Yang Y; Liu XH; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Aug; 46(8):606-610. PubMed ID: 30139010
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
    Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; Morandi E; van Eickels M; Cohen A
    Am Heart J; 2015 Apr; 169(4):464-71.e2. PubMed ID: 25819852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).
    Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; van Eickels M; Cohen A;
    Am Heart J; 2016 Aug; 178():126-34. PubMed ID: 27502860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban.
    Tsyganov A; Shapieva A; Sandrikov V; Fedulova S; Mironovich S; Dzeranova A; Lyan E
    BMC Cardiovasc Disord; 2017 Jun; 17(1):171. PubMed ID: 28662693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
    Gawałko M; Kapłon-Cieślicka A; Budnik M; Babiarz A; Bodys A; Uliński R; Żochowski M; Peller M; Scisło P; Kochanowski J; Filipiak KJ; Opolski G
    Pol Arch Intern Med; 2017 Dec; 127(12):823-831. PubMed ID: 28972957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.
    Ferner M; Wachtlin D; Konrad T; Deuster O; Meinertz T; von Bardeleben S; Münzel T; Seibert-Grafe M; Breithardt G; Rostock T
    Clin Res Cardiol; 2016 Jan; 105(1):29-36. PubMed ID: 26109251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients.
    Ke HH; He Y; Lv XW; Zhang EH; Wei Z; Li JY
    J Thromb Thrombolysis; 2019 Aug; 48(2):270-276. PubMed ID: 31165950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation.
    Fleddermann A; Eckert R; Muskala P; Hayes C; Magalski A; Main ML
    Am J Cardiol; 2019 Jan; 123(1):57-62. PubMed ID: 30376957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter.
    Hussain A; Katz WE; Genuardi MV; Bhonsale A; Jain SK; Kancharla K; Saba S; Shalaby AA; Voigt AH; Wang NC
    Pacing Clin Electrophysiol; 2019 Sep; 42(9):1183-1190. PubMed ID: 31355470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 3D Echocardiography Facilitates Analysis of Thrombolytic Efficacy in Patients With Persistent Atrial Fibrillation.
    Chen YF; Liu NN; Wang JY; Sun JS; Wang YX; Jiang HY; Zhou WW; Wang ZL; Liang M
    J Cardiovasc Pharmacol; 2024 Jul; 84(1):118-123. PubMed ID: 38547516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
    Pham PN; Brown JD
    BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].
    Szegedi N; Gellér L; Tahin T; Merkely B; Széplaki G
    Orv Hetil; 2016 Jan; 157(4):154-6. PubMed ID: 26772828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
    Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
    BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.